Scarica l'app Stockscreener
1.92
7.26%
0.13
Dopo l'orario di chiusura:
1.89
-0.03
-1.56%
Precedente Chiudi:
$1.79
Aprire:
$1.95
Volume 24 ore:
70,379
Relative Volume:
0.31
Capitalizzazione di mercato:
$164.27M
Reddito:
$47.04M
Utile/perdita netta:
$-63.98M
Rapporto P/E:
-2.381
EPS:
-0.8064
Flusso di cassa netto:
$-34.39M
1 W Prestazione:
-2.54%
1M Prestazione:
-8.13%
6M Prestazione:
-15.42%
1 anno Prestazione:
-25.29%
Intervallo 1D:
$1.91
$2.03
Intervallo di 1 settimana:
$1.76
$2.21
Portata 52W:
$1.29
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
Nome
Innate Pharma Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta IPHA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
1.92 | 164.27M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-09-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | Iniziato | Goldman | Neutral |
Innate Pharma Adr Borsa (IPHA) Ultime notizie
H.C. Wainwright maintains Buy rating on Innate Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Innate Pharma stock - Investing.com India
Innate Pharma Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances - Investing.com
Innate Pharma shares retain Buy rating on long-term strategy - Investing.com
AZN Stock Price and Chart — LSE:AZN - TradingView
Nebius Group N.V (NASDAQ: NBIS)’s Upward Trend Continues - Stocks Register
Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies By Investing.com - Investing.com UK
Contrast Security Introduces Application Detection and Response (ADR) to Identify and Block Attacks and Zero Days on Applications in Production - Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Business Wire
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
IPHA stock surges on upcoming presentation for AstraZeneca-partnered asset - Seeking Alpha
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
Innate Pharma Adr Azioni (IPHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):